At a glance
ClinicalIndex Comparison Record- ✓Adenocarcinoma of the rectum with specific staging: cT1-cT3ab, <5cm diameter, <½ circumference, N0-N1 (≤3 nodes <8mm), M0
- ✓ECOG performance status 0-1
- ✓Operable patient
- ✓Tumor accessible to endocavitary contact X-ray brachytherapy with distance from lower tumor border to anal verge ≤10cm
- ✕Inoperable patient
- ✕Advanced T-stage: T3cd, T4, or tumor ≥5cm or involving >½ bowel circumference
- ✕Distance from lower tumor border to anal verge >10cm
- ✕N2-status or N1 with any node ≥8mm diameter
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Contact Radiotherapy for Rectal Cancer (CORRECT): a Multicenter Randomized Phase II Trial
In Brief
A clinical study evaluating Radiotherapy, Short-course radiotherapy, and 2 other interventions for Rectal Cancer. Currently recruiting, targeting 110 participants across 2 sites.
Signals
Detailed Summary
The aim of the CORRECT phase 2 study is to show non-inferiority of Contact x-ray brachytherapy (CXB) + short-course radiotherapy (SCRT) compared to the experimental arm of the OPERA trial in organ preservation for early and early intermediate rectal cancer (cT1-3abN1).
Study Details
Timeline
Interventions
45/50 Gy (1.8/2 Gy/fraction/5 weeks)
25 Gy in 5 daily fractions over a total time of 1 week, treating 5 days per week, 1 fraction per day, using 5 Gy per fraction, over the maximum treatment period of eight calendar days
90Gy/3 fractions/4 weeks
Capecitabine (900 mg/m2 bid, on radiation days)